homovanillic acid has been researched along with Affective Psychosis, Bipolar in 109 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the effects of catecholamine depletion with alpha-methylparatyrosine (AMPT) on mood indices in patients with bipolar disorder who were in long-term remission with lithium therapy." | 9.09 | Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. ( Anand, A; Berman, RM; Cappiello, A; Charney, DS; Darnell, A; Miller, HL; Oren, DA; Woods, SW, 1999) |
| "Low gamma-aminobutyric acid (GABA) is implicated in both anxiety and depression pathophysiology." | 7.80 | Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. ( Boldrini, M; Cooper, TB; Currier, D; Ellis, SP; Malone, KM; Mann, JJ; Oquendo, MA; Sullivan, G; Watson, KT; Xie, S, 2014) |
| "In a mixed bipolar disorder patient, DST-positive, treated with neuroleptics and antidepressants, the addition of clonidine (up to 0." | 7.67 | Clonidine in the treatment of mixed bipolar disorder. ( Kontaxakis, V; Markianos, M; Markidis, M; Stefanis, C, 1989) |
| "This study investigated the effects of catecholamine depletion with alpha-methylparatyrosine (AMPT) on mood indices in patients with bipolar disorder who were in long-term remission with lithium therapy." | 5.09 | Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. ( Anand, A; Berman, RM; Cappiello, A; Charney, DS; Darnell, A; Miller, HL; Oren, DA; Woods, SW, 1999) |
| "Thirty-one consenting acute inpatient subjects between ages 19 and 66 years with a DSM-III-R clinical diagnosis of bipolar disorder, manic with psychotic features were entered into this double-blind study and were randomly assigned to receive either haloperidol 25 mg/day or haloperidol 5 mg for the 3-week study." | 5.09 | Pretreatment plasma HVA and haloperidol response in acute mania. ( Bebe, R; Chang, WH; Charles, O; Chou, JC; Cooper, TB; Czobor, P; Lane, HY; Stone, DL; Tuma, I, 2000) |
| "Low gamma-aminobutyric acid (GABA) is implicated in both anxiety and depression pathophysiology." | 3.80 | Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. ( Boldrini, M; Cooper, TB; Currier, D; Ellis, SP; Malone, KM; Mann, JJ; Oquendo, MA; Sullivan, G; Watson, KT; Xie, S, 2014) |
| "In this study, plasma obtained from monozygotic twin pairs discordant for schizophrenia (n = 10) or major affective disorder (n = 3) was assayed for epinephrine, norepinephrine, dihydroxyphenylacetic acid, homovanillic acid, adrencorticotropin hormone, and cortisol." | 3.71 | Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. ( Bonsall, R; Walder, DJ; Walker, EF, 2002) |
| "In 8 cases of typical neuroleptic malignant syndrome (NMS), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA), noradrenaline (NA), and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) levels in the cerebrospinal fluid (CSF) were assayed during both the active phase of NMS and after recovery." | 3.68 | Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. ( Ishiguro, T; Nisijima, K, 1990) |
| "Lateral ventricle enlargement in schizophrenia has been positively correlated with poor premorbid competence, negative symptoms, and poor treatment response and negatively correlated with concentrations of homovanillic acid (HVA), a dopaminergic metabolite." | 3.68 | Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia. ( Caudle, J; Eccard, M; Jewart, RD; Lewine, RR; Pollard, W; Risby, E; Risch, SC; Stipetic, M, 1991) |
| "CSF levels of radioreceptorassayed endorphins Fraction I (EndFI, n = 92) and homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) (n = 118) were measured in patients with major depressive disorders according to Research Diagnostic Criteria (18% were psychotic; 11% hallucinated during the peak of the depressive episode)." | 3.67 | Hallucinations in patients with major depression. Interactions between CSF monoaminergic and endorphinergic indices. ( Agren, H; Terenius, L, 1985) |
| "The effects of electroconvulsive therapy (ECT) on sleep and cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) were studied in 11 male patients suffering from major depressive disorders severe enough to require ECT." | 3.67 | Effects of ECT on sleep and CSF biogenic amines in affective illness. ( Desmedt, D; Hoffmann, G; Kerkhofs, M; Linkowski, P; Mendlewicz, J, 1985) |
| "In a mixed bipolar disorder patient, DST-positive, treated with neuroleptics and antidepressants, the addition of clonidine (up to 0." | 3.67 | Clonidine in the treatment of mixed bipolar disorder. ( Kontaxakis, V; Markianos, M; Markidis, M; Stefanis, C, 1989) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the spinal fluid of 45 women hospitalized in a psychiatric department for major depression (14 cases), schizophrenia (18 cases) and alcohol dependence (13 cases)." | 3.66 | Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients. ( Arató, M; Banki, CM, 1983) |
| "The metabolites of serotonin, dopamine, and norepinephrine, 5-hydroxyindoleacetic acid (5HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxy-phenylethylene glycol (MHPG), respectively, were studied in cerebrospinal fluid of patients with acute schizophrenia." | 3.65 | Cerebrospinal fluid amine metabolites in acute schizophrenia. ( Carpenter, WT; Fink, E; Goodwin, FK; Post, RM, 1975) |
| "The probenecid technique was used in study of the central dopamine DA metabolism in patients with depressions, psychotic disorders, and Parkinson's disease." | 3.65 | Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. ( Korf, J; Praag, HM; Schut, T, 1975) |
| "Furthermore, the response to sleep deprivation has important research implications." | 2.37 | Clinical and biological correlates of sleep deprivation in depression. ( Brown, P; Joffe, RT, 1984) |
| "One hundred nine bipolar, 324 major depressive disorder, and 130 healthy volunteers were genotyped for the rs4131347 (-C8347G) promoter SNP." | 1.35 | No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover. ( Brent, D; Currier, D; Galfalvy, H; Greenhill, L; Huang, YY; Mann, JJ; Murphy, L; Oquendo, M, 2008) |
| "Responders with bipolar depression had smaller reductions in MHPG levels than did responders with unipolar depression." | 1.27 | Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. ( Bowden, CL; Davis, JM; Hanin, I; Koslow, SH; Maas, JW; Robins, E, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 76 (69.72) | 18.7374 |
| 1990's | 15 (13.76) | 18.2507 |
| 2000's | 12 (11.01) | 29.6817 |
| 2010's | 6 (5.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knorr, U | 1 |
| Simonsen, AH | 1 |
| Zetterberg, H | 1 |
| Blennow, K | 2 |
| Hasselbalch, SG | 1 |
| Kessing, LV | 1 |
| Arrúe, A | 5 |
| González-Torres, MA | 4 |
| Basterreche, N | 5 |
| Arnaiz, A | 1 |
| Olivas, O | 1 |
| Zamalloa, MI | 4 |
| Erkoreka, L | 1 |
| Catalán, A | 1 |
| Zumárraga, M | 5 |
| Mann, JJ | 4 |
| Oquendo, MA | 3 |
| Watson, KT | 1 |
| Boldrini, M | 1 |
| Malone, KM | 1 |
| Ellis, SP | 1 |
| Sullivan, G | 1 |
| Cooper, TB | 2 |
| Xie, S | 1 |
| Currier, D | 3 |
| Kurita, M | 1 |
| Nishino, S | 1 |
| Numata, Y | 1 |
| Okubo, Y | 1 |
| Sato, T | 1 |
| Milienne-Petiot, M | 1 |
| Kesby, JP | 1 |
| Graves, M | 1 |
| van Enkhuizen, J | 1 |
| Semenova, S | 1 |
| Minassian, A | 1 |
| Markou, A | 1 |
| Geyer, MA | 1 |
| Young, JW | 1 |
| Galfalvy, H | 2 |
| Huang, YY | 3 |
| Dávila, R | 4 |
| Anguiano, JB | 3 |
| Guimón, J | 3 |
| Goienetxea, B | 2 |
| Rydén, E | 1 |
| Johansson, C | 1 |
| Landén, M | 1 |
| Yoshimura, R | 2 |
| Nakano, Y | 1 |
| Hori, H | 1 |
| Ikenouchi, A | 1 |
| Ueda, N | 2 |
| Nakamura, J | 2 |
| Sher, L | 1 |
| Carballo, JJ | 1 |
| Grunebaum, MF | 1 |
| Burke, AK | 1 |
| Zalsman, G | 1 |
| Shinkai, K | 1 |
| Murphy, L | 1 |
| Brent, D | 1 |
| Greenhill, L | 1 |
| Oquendo, M | 1 |
| Joffe, RT | 1 |
| Brown, P | 1 |
| Post, RM | 10 |
| Jimerson, DC | 4 |
| Bunney, WE | 4 |
| Goodwin, FK | 14 |
| Leckman, JF | 1 |
| Cohen, DJ | 2 |
| Shaywitz, BA | 2 |
| Caparulo, BK | 1 |
| Heninger, GR | 2 |
| Bowers, MB | 8 |
| Rosenthal, NE | 2 |
| Davenport, Y | 1 |
| Cowdry, RW | 2 |
| Webster, MH | 1 |
| Anokhina, IP | 1 |
| Gamaleia, NB | 1 |
| Davis, KL | 1 |
| Hollister, LE | 1 |
| Mathé, AA | 1 |
| Davis, BM | 1 |
| Rothpearl, AB | 1 |
| Faull, KF | 2 |
| Hsieh, JY | 1 |
| Barchas, JD | 1 |
| Berger, PA | 1 |
| Agren, H | 4 |
| Taylor, MA | 1 |
| Abrams, R | 1 |
| Oreland, L | 1 |
| Wide, L | 1 |
| Swann, AC | 3 |
| Secunda, S | 1 |
| Davis, JM | 5 |
| Robins, E | 4 |
| Hanin, I | 3 |
| Koslow, SH | 6 |
| Maas, JW | 9 |
| Korf, J | 2 |
| van den Burg, W | 1 |
| van den Hoofdakker, RH | 1 |
| Banki, CM | 4 |
| Arató, M | 3 |
| Papp, Z | 2 |
| Kurcz, M | 1 |
| Bowden, CL | 4 |
| Javaid, J | 2 |
| Asberg, M | 1 |
| Bertilsson, L | 1 |
| Mårtensson, B | 1 |
| Scalia-Tomba, GP | 1 |
| Thorén, P | 1 |
| Träskman-Bendz, L | 1 |
| Katz, MM | 5 |
| Gibbons, RL | 1 |
| Stokes, PE | 2 |
| Gerner, RH | 4 |
| Fairbanks, L | 1 |
| Anderson, GM | 1 |
| Young, JG | 1 |
| Scheinin, M | 3 |
| Linnoila, M | 6 |
| Hare, TA | 1 |
| Karoum, F | 1 |
| Potter, WZ | 2 |
| Kasa, K | 1 |
| Otsuki, S | 1 |
| Yamamoto, M | 1 |
| Sato, M | 1 |
| Kuroda, H | 1 |
| Ogawa, N | 1 |
| Young, LT | 1 |
| Warsh, JJ | 1 |
| Kish, SJ | 1 |
| Shannak, K | 1 |
| Hornykeiwicz, O | 1 |
| Markianos, M | 2 |
| Alevizos, B | 1 |
| Hatzimanolis, J | 1 |
| Stefanis, C | 2 |
| Frazer, A | 1 |
| Berman, N | 1 |
| Rudorfer, MV | 2 |
| Skwerer, RG | 1 |
| Mazure, CM | 4 |
| Kelley, ME | 1 |
| Yao, JK | 1 |
| van Kammen, DP | 1 |
| Anand, A | 1 |
| Darnell, A | 1 |
| Miller, HL | 1 |
| Berman, RM | 1 |
| Cappiello, A | 1 |
| Oren, DA | 1 |
| Woods, SW | 1 |
| Charney, DS | 1 |
| Chou, JC | 1 |
| Czobor, P | 1 |
| Tuma, I | 1 |
| Charles, O | 1 |
| Bebe, R | 1 |
| Chang, WH | 1 |
| Lane, HY | 1 |
| Stone, DL | 1 |
| Walker, EF | 1 |
| Bonsall, R | 1 |
| Walder, DJ | 1 |
| Fortunati, F | 1 |
| Mazure, C | 1 |
| Preda, A | 1 |
| Wahl, R | 1 |
| Bowers, M | 1 |
| Roccatagliata, G | 1 |
| Albano, C | 1 |
| Cocito, L | 1 |
| Maffini, M | 1 |
| Carman, JS | 1 |
| Gillin, JC | 2 |
| Praag, HM | 2 |
| Gold, PW | 1 |
| Wehr, T | 1 |
| Rebar, R | 1 |
| Vestergaard, P | 1 |
| Sørensen, T | 1 |
| Hoppe, E | 1 |
| Rafaelsen, OJ | 1 |
| Yates, CM | 1 |
| Nicolaou, N | 1 |
| Ban, TA | 1 |
| Fyrö, B | 2 |
| Petterson, U | 1 |
| Sedvall, G | 2 |
| Subrahmanyam, S | 1 |
| Fink, E | 1 |
| Carpenter, WT | 1 |
| Schut, T | 1 |
| Gordon, EK | 1 |
| Nelson, JC | 3 |
| Jatlow, PI | 3 |
| Nisijima, K | 1 |
| Ishiguro, T | 1 |
| Lewine, RR | 1 |
| Risch, SC | 1 |
| Risby, E | 1 |
| Stipetic, M | 1 |
| Jewart, RD | 1 |
| Eccard, M | 1 |
| Caudle, J | 1 |
| Pollard, W | 1 |
| Roy, A | 5 |
| Dejong, J | 1 |
| Ferraro, T | 1 |
| Baker, NJ | 1 |
| Staunton, M | 1 |
| Adler, LE | 2 |
| Gerhardt, GA | 2 |
| Drebing, C | 2 |
| Waldo, M | 1 |
| Nagamoto, H | 2 |
| Freedman, R | 2 |
| Franks, R | 1 |
| Baker, N | 1 |
| Terenius, L | 1 |
| Pickar, D | 3 |
| Doran, AR | 2 |
| Ninan, P | 1 |
| Paul, SM | 2 |
| Golden, RN | 2 |
| Calil, HM | 1 |
| Ross, RJ | 1 |
| Modai, I | 1 |
| Beigel, Y | 1 |
| Cygielman, G | 1 |
| Hoffmann, G | 3 |
| Linkowski, P | 1 |
| Kerkhofs, M | 1 |
| Desmedt, D | 1 |
| Mendlewicz, J | 1 |
| Redmond, DE | 1 |
| Swann, A | 1 |
| Casper, R | 1 |
| Brown, GL | 1 |
| Secunda, SK | 2 |
| Cross, CK | 1 |
| Koslow, S | 1 |
| Kocsis, JH | 1 |
| Csernansky, JG | 1 |
| Pfefferbaum, A | 1 |
| Tandon, R | 1 |
| Channabasavanna, SM | 1 |
| Greden, JF | 1 |
| Kontaxakis, V | 1 |
| Markidis, M | 1 |
| De Jong, J | 1 |
| Berrettini, WH | 1 |
| Nurnberger, JI | 1 |
| Seppala, T | 1 |
| Narrow, W | 1 |
| Simmons-Alling, S | 1 |
| Gershon, ES | 1 |
| Wolkowitz, OM | 2 |
| Doran, A | 1 |
| Breier, A | 2 |
| Kruzik, P | 1 |
| Sofic, E | 1 |
| Riederer, P | 1 |
| Gabriel, E | 1 |
| Sutton, ME | 1 |
| Syvälahti, E | 1 |
| Ashcroft, GW | 1 |
| Blackburn, IM | 1 |
| Eccleston, D | 1 |
| Glen, AI | 1 |
| Hartley, W | 1 |
| Kinloch, NE | 1 |
| Lonergan, M | 1 |
| Murray, LG | 1 |
| Pullar, IA | 1 |
| Schildkraut, JJ | 1 |
| Ackenheil, M | 2 |
| Beckmann, H | 2 |
| Markianos, E | 2 |
| Nyström, I | 1 |
| Raese, J | 2 |
| Nybäck, H | 1 |
| Wiesel, FA | 1 |
| Wode-Helgodt, B | 1 |
| Sjöström, R | 2 |
| Sack, RL | 3 |
| Savage, C | 2 |
| Messiha, FS | 2 |
| Rosenblatt, S | 1 |
| Leighton, WP | 1 |
| Chanley, JD | 1 |
| Turek, I | 1 |
| Hanlon, TE | 1 |
| Greil, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects[NCT05195203] | Phase 1 | 96 participants (Actual) | Interventional | 2021-01-27 | Completed | ||
| [NCT00004325] | 200 participants | Observational | 1988-12-31 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
9 reviews available for homovanillic acid and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review.
Topics: Biomarkers; Bipolar Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid | 2018 |
Clinical and biological correlates of sleep deprivation in depression.
Topics: Bipolar Disorder; Circadian Rhythm; Depressive Disorder; Homovanillic Acid; Humans; Hydrocortisone; | 1984 |
Reassessing the bipolar-unipolar dichotomy.
Topics: Bipolar Disorder; Catechol O-Methyltransferase; Depressive Disorder; Diagnosis, Differential; Female | 1980 |
The switch process in manic-depressive psychosis.
Topics: Amphetamines; Animals; Bipolar Disorder; Calcium; Cyclic AMP; Cyclic GMP; Electroencephalography; Ho | 1977 |
Studies of amine metabolites in affective illness and in schizophrenia: a comparative analysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antidepressive Agents, Tricyclic; Bipolar Disorder; Brain; Depressio | 1975 |
Pharmacotherapy of depression--a critical review.
Topics: Adjustment Disorders; Antidepressive Agents, Tricyclic; Bipolar Disorder; Brain; Depression; Dopamin | 1975 |
Simulated behavior states: an approach to specificity in psychobiological research.
Topics: Biology; Bipolar Disorder; Cyclic AMP; Depression; Emotions; Homovanillic Acid; Humans; Hydroxyindol | 1973 |
Biogenic amines and affective disorders.
Topics: Affective Symptoms; Biogenic Amines; Bipolar Disorder; Blood Platelets; Brain; Catechol O-Methyltran | 1974 |
Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover.
Topics: Adult; Affective Symptoms; Anger; Bipolar Disorder; Central Nervous System; Depression; Diagnosis, D | 1974 |
13 trials available for homovanillic acid and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Plasma homovanillic acid and family history of psychotic disorders in bipolar I patients.
Topics: Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Family Health | 2009 |
Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Catecholamines; Ch | 2006 |
Effects of antidepressant treatments on dopamine turnover in depressed patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antidepressive Agents; Bipolar Disorder; Brompheniramine; Clo | 1983 |
Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients.
Topics: Amitriptyline; Behavior; Bipolar Disorder; Brain Chemistry; Depressive Disorder; Double-Blind Method | 1994 |
Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder.
Topics: Adult; alpha-Methyltyrosine; Antimanic Agents; Bipolar Disorder; Catecholamines; Double-Blind Method | 1999 |
Pretreatment plasma HVA and haloperidol response in acute mania.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug | 2000 |
Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depression; Double-Blind Method; Female; Homovani | 1978 |
The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Female; Homovanillic Acid; Huma | 1975 |
Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Clorgyline; Depressive Disorder; Desipramine; Female; Gly | 1985 |
Estimation of brain amine metabolism in affective illness: cerebrospinal fluid studies utilizing probenecid.
Topics: Bipolar Disorder; Brain; Depression; Dihydroxyphenylalanine; Fenclonine; Homovanillic Acid; Humans; | 1974 |
5-Hydroxyindole acetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis and the effect of probenecid treatment.
Topics: Adult; Age Factors; Aged; Bipolar Disorder; Body Weight; Clinical Trials as Topic; Female; Half-Life | 1973 |
Inhibition of dopamine-b-hydroxylase in manic patients. A clinical trial and fusaric acid.
Topics: Bipolar Disorder; Clinical Trials as Topic; Dopamine; Dopamine beta-Hydroxylase; Enzyme Inhibitors; | 1974 |
Behavioral effects of a new dopamine-beta-hydroxylase inhibitor (fusaric acid) in man.
Topics: Administration, Oral; Bipolar Disorder; Clinical Trials as Topic; Depression; Dopamine beta-Hydroxyl | 1974 |
87 other studies available for homovanillic acid and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
GAD1 gene polymorphisms are associated with bipolar I disorder and with blood homovanillic acid levels but not with plasma GABA levels.
Topics: Adult; Biomarkers; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Haplo | 2019 |
Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid.
Topics: Adult; Age Factors; Anxiety; Bipolar Disorder; Case-Control Studies; Chromatography, High Pressure L | 2014 |
The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study.
Topics: Adult; Aged; Antipsychotic Agents; Biomarkers; Bipolar Disorder; Brain-Derived Neurotrophic Factor; | 2014 |
The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania.
Topics: Animals; Bipolar Disorder; Brain Chemistry; Conditioning, Operant; Disease Models, Animal; Dopamine | 2017 |
Increased risk of suicide attempt in mood disorders and TPH1 genotype.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Black or African American; Depressive Disorder, Major; Fe | 2009 |
Biological correlates of the congruence and incongruence of psychotic symptoms in patients with type 1 bipolar disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Bipolar Disorder; Catechol O-Methyltransferase; Female; Genot | 2008 |
GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.
Topics: Adolescent; Adult; Biomarkers; Bipolar Disorder; Dopamine; Female; gamma-Aminobutyric Acid; Homovani | 2010 |
Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Female; Follow-Up Studies; H | 2009 |
Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biogenic Monoamines; Bipolar Disorder; Catechol O-Meth | 2006 |
A prospective study of the association of cerebrospinal fluid monoamine metabolite levels with lethality of suicide attempts in patients with bipolar disorder.
Topics: Adult; Bipolar Disorder; Demography; Female; Follow-Up Studies; Homovanillic Acid; Humans; Hydroxyin | 2006 |
Two cases of bipolar disorder successfully stabilized for five years with a low dose of risperidone and lithium.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Homovanillic Acid; Humans; | 2006 |
No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover.
Topics: Adult; Bipolar Disorder; Child; Child Abuse; Depressive Disorder, Major; Female; Genotype; Homovanil | 2008 |
Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide.
Topics: Adult; Behavior; Bipolar Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1980 |
CSF monoamine metabolites in child and adult psychiatric patients. A developmental perspective.
Topics: Adolescent; Adult; Age Factors; Aged; Autistic Disorder; Bipolar Disorder; Child; Child, Preschool; | 1980 |
Monoamine metabolites in cerebrospinal fluid of depressive subgroups.
Topics: Adult; Alcoholism; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans | 1980 |
[Current biochemical conceptions of mental diseases. II. Role of changes in the biogenic amine system in the pathogenesis of affective disorders].
Topics: 3-Methoxy-4-hydroxyphenylethanol; Affective Disorders, Psychotic; Antidepressive Agents, Tricyclic; | 1980 |
Neuroendocrine and neurochemical measurements in depression.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Dexamethasone; Glycols; Homovanillic Acid; Human | 1981 |
Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: I. General patterns.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans; Hydr | 1980 |
Early morning awakening in unipolar depressives with higher levels of platelet MAO activity.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Blood Platelets; Depressive Disorder; Female; Homovanilli | 1982 |
Patterns of depression reflected in pituitary - thyroid and pituitary - adrenal endocrine changes.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depressive Disorder; Dexamethasone; Homovanillic Acid; Hu | 1982 |
CSF monoamine metabolites in mania.
Topics: Adult; Affective Disorders, Psychotic; Aged; Bipolar Disorder; Female; Glycols; Homovanillic Acid; H | 1983 |
Acid metabolites and precursor amino acids of 5-hydroxytryptamine and dopamine in affective and other psychiatric disorders.
Topics: Adjustment Disorders; Adult; Aged; Amino Acids; Bipolar Disorder; Depressive Disorder; Dopamine; Fem | 1983 |
Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients.
Topics: Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; | 1983 |
The effect of dexamethasone on cerebrospinal fluid monoamine metabolites and cortisol in psychiatric patients.
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1983 |
CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis.
Topics: Adult; Affective Disorders, Psychotic; Biogenic Amines; Bipolar Disorder; Depressive Disorder; Epine | 1983 |
Cerebrospinal fluid biochemical examinations: do they reflect clinical or biological differences?
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Calcium; Depressive Disorder; Dexamethasone; Female; Homo | 1983 |
CSF monoamine metabolites in melancholia.
Topics: Adult; Age Factors; Aged; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; | 1984 |
Some clinical and biochemical predictors of outcome in depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid | 1984 |
Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder; Female; Homo | 1984 |
CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.
Topics: Adolescent; Adult; Age Factors; Aged; Bipolar Disorder; Calcium; Choline; Depressive Disorder; Femal | 1984 |
Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders.
Topics: Adult; Age Factors; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Homovani | 1982 |
Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder.
Topics: Adult; Bipolar Disorder; Brain Chemistry; Brain Mapping; Dopamine; Female; Homovanillic Acid; Humans | 1994 |
Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
Topics: Adult; Arousal; Benzamides; Biogenic Amines; Bipolar Disorder; Chromatography, High Pressure Liquid; | 1994 |
Biogenic amines in seasonal affective disorder: effects of light therapy.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1993 |
Pretreatment plasma HVA predicts neuroleptic response in manic psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Female; Haloperidol; Homovanillic Acid; H | 1998 |
Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Bipolar Disorder; Catecholamines; Homovanillic Acid; Humans | 1999 |
Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adrenocorticotropic Hormone; Adult; Bipolar Disorder; Ca | 2002 |
Plasma catecholamine metabolites in antidepressant-exacerbated mania and psychosis.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Catecholamines; Comorbidity; Female; Homovanillic Ac | 2002 |
Interactions between central monoaminergic systems: dopamine-serotonin.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depression; Dopamine; Dyskinesia, Drug-Induced; Female; H | 1979 |
Biological and behavioral effects of one night's sleep deprivation in depressed patients and normals.
Topics: Adult; Aged; Bipolar Disorder; Body Temperature; Calcium; Circadian Rhythm; Depression; Electroencep | 1979 |
Biochemistry of the affective disorders.
Topics: Affective Symptoms; Bipolar Disorder; Body Temperature; Cholinesterase Inhibitors; Circadian Rhythm; | 1979 |
The Harold E. Himwich Memorial Lecture. Significance of biochemical parameters in the diagnosis, treatment, and prevention of depressive disorders.
Topics: 5-Hydroxytryptophan; Antidepressive Agents, Tricyclic; Autopsy; Bipolar Disorder; Brain Chemistry; C | 1977 |
Pituitary thyrotropin response to thyrotropin-releasing hormone in affective illness: relationship to spinal fluid amine metabolites.
Topics: Age Factors; Bipolar Disorder; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1977 |
Lithium: clinical effects and cerebrospinal fluid acid monoamine metabolites.
Topics: Adult; Affective Symptoms; Aged; Biogenic Amines; Bipolar Disorder; Depression; Electroencephalograp | 1977 |
Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders.
Topics: Adult; Aged; Biogenic Amines; Bipolar Disorder; Depression; Female; Homovanillic Acid; Humans; Hydro | 1978 |
A dopaminergic mechanism in mania.
Topics: Bipolar Disorder; Depression; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Lithium | 1976 |
CSF acid monoamine metabolities as a possible reflection of central MAO activity in chronic schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chronic Disease; Female; Homovanillic Acid; Huma | 1976 |
Role of biogenic amines in certain pathological conditions.
Topics: Acute Disease; Adult; Aggression; Biogenic Amines; Bipolar Disorder; Chlorpromazine; Chronic Disease | 1975 |
Cerebrospinal fluid amine metabolites in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Amines; Bipolar Disorder; Dopamine; Homovanillic Acid; Humans; Hyd | 1975 |
Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders.
Topics: Adjustment Disorders; Bipolar Disorder; Brain; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; D | 1975 |
Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients.
Topics: Bipolar Disorder; Brain; Chlorpromazine; Dopamine; Homovanillic Acid; Humans; Schizophrenia; Thiorid | 1975 |
Central noradrenergic function in man: vanillylmandelic acid in CSF.
Topics: Acute Disease; Affective Symptoms; Bipolar Disorder; Depression; Homovanillic Acid; Humans; Hydroxyi | 1975 |
Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
Topics: Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Lithium | 1992 |
Neuroleptic malignant syndrome: a study of CSF monoamine metabolism.
Topics: Adult; Biogenic Monoamines; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid; Humans | 1990 |
Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia.
Topics: Adult; Age Factors; Bipolar Disorder; Body Height; Body Weight; Brain; Brain Chemistry; Cerebral Ven | 1991 |
CSF GABA in depressed patients and normal controls.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Homovanillic Acid; Hu | 1991 |
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Depressive | 1991 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups.
Topics: Adult; Arousal; Attention; Bipolar Disorder; Brain; Catecholamines; Depressive Disorder; Evoked Pote | 1990 |
Sensory physiology and catecholamines in schizophrenia and mania.
Topics: Adult; Arousal; Bipolar Disorder; Dopamine; Electroencephalography; Evoked Potentials, Auditory; Fem | 1990 |
Hallucinations in patients with major depression. Interactions between CSF monoaminergic and endorphinergic indices.
Topics: Adult; Age Factors; Bipolar Disorder; Depressive Disorder; Endorphins; Female; Hallucinations; Homov | 1985 |
Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Bipolar Disorder; Depressive Disorder; Dopamine; Female | 1985 |
Urinary amine metabolite excretion in a patient with adrenergic hyperactivity state: reaction to phenelzine withdrawal and combined treatment.
Topics: Bipolar Disorder; Delirium; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Meta | 1986 |
Effects of ECT on sleep and CSF biogenic amines in affective illness.
Topics: Adult; Biogenic Amines; Bipolar Disorder; Depressive Disorder; Electroconvulsive Therapy; Homovanill | 1985 |
Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects.
Topics: Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Hospitalization; Humans; | 1986 |
Cerebrospinal fluid correlates of suicide attempts and aggression.
Topics: Aggression; Animals; Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindole | 1986 |
Studies of amine metabolites in depressed patients. Relationship to suicidal behavior.
Topics: Bipolar Disorder; Brain; Depressive Disorder; Epinephrine; Homovanillic Acid; Humans; Hydrocortisone | 1986 |
Lithium carbonate treatment of mania. Cerebrospinal fluid and urinary monoamine metabolites and treatment outcome.
Topics: Adult; Aged; Bipolar Disorder; Brain; Dopamine; Epinephrine; Female; Homovanillic Acid; Humans; Hydr | 1987 |
Seasonal changes of CSF monoamine metabolites in psychiatric patients: what is the source?
Topics: Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mental D | 1988 |
CSF biochemical correlates of mixed affective states.
Topics: Adult; Bipolar Disorder; Calcium; Depressive Disorder; Electrolytes; Female; Homovanillic Acid; Huma | 1988 |
Clonidine in the treatment of mixed bipolar disorder.
Topics: Adult; Bipolar Disorder; Clonidine; Dexamethasone; Dopamine beta-Hydroxylase; Female; Homovanillic A | 1989 |
Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Dopamine; Female; Follow-Up Studies; Homovanillic Acid | 1989 |
Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid.
Topics: Adult; Amitriptyline; Bipolar Disorder; Depressive Disorder; Dopamine; Double-Blind Method; Female; | 1985 |
Cerebrospinal fluid and plasma monoamines and their metabolites in euthymic bipolar patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Bipolar Disorder; Dopamine; Homovanillic Acid; Humans; Hydroxyindole | 1985 |
Specificity of plasma HVA response to dexamethasone in psychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; | 1989 |
Biochemical aspects of dysphoria: case study for hypothesis generation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Affective Disorders, Psychotic; Aged; Bipolar Disorder; Brain; Depre | 1987 |
The effects of dexamethasone on plasma homovanillic acid and 3-methoxy-4-hydroxyphenylglycol. Evidence for abnormal corticosteroid-catecholamine interactions in major depression.
Topics: Adult; Aged; Bipolar Disorder; Circadian Rhythm; Depressive Disorder; Dexamethasone; Diagnosis, Diff | 1987 |
Dexamethasone suppression test and the levels of serum growth hormone, plasma vasopressin and plasma homovanillic acid in depressed in- and outpatients.
Topics: Adolescent; Adult; Aged; Arginine Vasopressin; Bipolar Disorder; Depressive Disorder; Dexamethasone; | 1985 |
Changes on recovery in the concentrations of tryptophan and the biogenic amine metabolites in the cerebrospinal fluid of patients with affective illness.
Topics: Adult; Affective Symptoms; Antipsychotic Agents; Biogenic Amines; Bipolar Disorder; Butyrophenones; | 1973 |
[Effect of clozapine on the excretion of 3-methoxy-4-hydroxy-phenylglycol, homovanillic acid and 5-hydroxy-indole acetic acid in urine and cerebrospinal fluid].
Topics: Azepines; Bipolar Disorder; Dopamine beta-Hydroxylase; Glycols; Homovanillic Acid; Humans; Hydroxyin | 1974 |
Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Bipolar Disorder; Brain; Chlorpromazine; Chromatography, Gas; Deuterium; Dopamin | 1974 |
Psychiatric and biochemical profiles of lithium therapy in mania. (Case report).
Topics: Adult; Bipolar Disorder; Dopamine; Female; Homovanillic Acid; Humans; Lithium; Norepinephrine; Norme | 1972 |
Dopamine-beta-hydroxylase: evidence for increased activity in sympathetic neurons during psychotic states.
Topics: Bipolar Disorder; Dopamine; Dopamine beta-Hydroxylase; Homovanillic Acid; Humans; Male; Methoxyhydro | 1973 |
Lumbar CSF 5-hydroxyindoleacetic acid and homovanillic acid in affective syndromes.
Topics: Adult; Affective Symptoms; Amitriptyline; Animals; Bipolar Disorder; Brain Chemistry; Cats; Depressi | 1974 |
A psychopharmacological study of catecholamines in affective disorders.
Topics: Adult; Affective Symptoms; Bipolar Disorder; Catecholamines; Dopamine; Electroconvulsive Therapy; Fe | 1974 |
Antipsychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man.
Topics: Bipolar Disorder; Carbon Radioisotopes; Catecholamines; Chromatography, Gas; Dibenzazepines; Dopamin | 1974 |
Diagnosis of manic-depressive psychosis from cerebrospinal fluid concentration of 5-hydroxyindoleacetic acid.
Topics: Bipolar Disorder; Dose-Response Relationship, Drug; Half-Life; Homovanillic Acid; Humans; Hydroxyind | 1974 |